Early-onset gastric cancer: Learning lessons from the young

Anya N Milne, G Johan A Offerhaus

Abstract
There is by no means a clear-cut pattern of mutations contributing to gastric cancers, and gastric cancer research can be hampered by the diversity of factors that can induce gastric cancer, such as *Helicobacter pylori* infection, diet, ageing and other environmental factors. Tumours are unquestionably riddled with genetic changes yet we are faced with an unsolvable puzzle with respect to a temporal relationship. It is postulated that inherited genetic factors may be more important in early-onset gastric cancer (EOGC) than in gastric cancers found in older patients as they have less exposure to environmental carcinogens. EOGC, therefore, could provide a key to unravelling the genetic changes in gastric carcinogenesis. Gastric cancers occurring in young patients provide an ideal background on which to try and uncover the initiating stages of gastric carcinogenesis. This review summarizes the literature regarding EOGC and also presents evidence that these cancers have a unique molecular-genetic phenotype, distinct from conventional gastric cancer.

© 2010 Baishideng. All rights reserved.

**Key words:** Gastric cancer; Early-onset gastric cancer; *Helicobacter pylori*
dysplasia, and thus intestinal metaplasia is considered to be a dependable morphological marker for gastric cancer risk. Unlike intestinal gastric cancer, the diffuse type typically develops following chronic inflammation without passing through the intermediate steps of atrophic gastritis or intestinal metaplasia.

Several classification systems have been proposed, but the most commonly used are those of the WHO and of Laurén who describes two main histological types, diffuse and intestinal.[7] Intestinal adenocarcinoma predominates in high-risk areas whereas the diffuse adenocarcinoma is more common in low-risk areas.[11] Although classification varies between Japan and the West, attempts have been made recently to standardize systems.[22] Early gastric cancer is a term to describe carcinomas limited to the mucosa or to both the mucosa and submucosa, regardless of nodal status. The prevalence of this lesion is higher in countries such as Japan, where a screening programme is carried out.

There is no means a clear-cut pattern of mutations in gastric cancers, with no known multi-step pathway, and genetic research can often be hampered by the diversity of changes that are induced by Helicobacter pylori infection, diet, ageing and other environmental factors. Tumours are unquestionably riddled with genetic changes, as summarized in Figure 1, yet we are faced with an unsolvable puzzle with respect to a temporal relationship. In order to solve this problem, one approach is to investigate tumours that are less influenced by these environmental factors. Gastric cancers occurring in young patients, known as early-onset gastric cancers (EOGC), provide an ideal background on which to try and uncover the initiating stages in gastric carcinogenesis. In addition, hereditary cancers can often illuminate discrete mutations that can initiate the pathway of gastric carcinogenesis.

**EARLY ONSET GASTRIC CANCER**

Gastric cancer is rare below the age of 30 thereafter it increases rapidly and steadily to reach the highest rates in the oldest age groups, both in males and females. EOGC is defined as gastric cancer presenting at the age of 45 or younger. Approximately 10% of gastric cancer patients fall into the EOGC category,[3] although rates vary between 2%-3%[14] and 5%-15%[13,15] depending on the population studied. Young patients more frequently develop diffuse lesions, which often arise on the background of historically “normal” gastric mucosa. It is postulated that genetic factors may be more important in EOGC than in older patients as younger patients have less exposure to environmental carcinogens,[5,16], thus these cancers could provide a key to unravelling the genetic changes in gastric carcinogenesis. H. pylori may still play a role in the development of gastric cancer in young patients,[17-19] and there is, in fact, no difference in the distribution of gastric cancer predisposing IL1B polymorphisms between young and old patients.[20] However, the role of H. pylori is likely to involve a much smaller percentage of patients than in the older age group. Epstein-Barr virus (EBV), which is observed in 7%-20% of gastric cancers, has been implicated in gastric carcinogenesis and occurs slightly more frequently in diffuse-type gastric cancers.[21-23] However, the levels of EBV infection appear to be much lower (or absent) in EOGC.[24]

The clinicopathological features of gastric carcinoma are said to differ between young and elderly patients[25] and it has been claimed that young patients have a poorer prognosis[26]. Others report that tumour staging and prognosis for young patients is similar to older patients and depends on whether the patients undergo a curative resection[13,15,27]. Young patients with gastric cancer in the United States are more likely to be black, Asian or Hispanic[28]. Relative to older patients, young patients have a female preponderance, a more frequent occurrence of diffuse cancer and less intestinal metaplasia[13,15,26-29]. This predominance of females is considered by some to be due to hormonal factors[30,31]. Cancers in young patients are more often multifocal than in older patients[32] as is also seen in HDGC.[33]

Approximately 10% of young gastric cancer patients have a positive family history[34], some of which are accounted for in inherited gastric cancer predisposition syndromes. Although the underlying genetic events are not always known, it can involve CDH1 germline mutations[34,35], encoding an aberrant form of E-cadherin, resulting in hereditary diffuse gastric cancer (HDGC), as recently reviewed by Carneiro et al.[36]. In fact, some suggest that when looking at hMLH1 and CDH1 germline mutations, 2%-3% of EOCG cases in North Americans may be due to high-risk genetic mutations[37,38]. The 90% without a family history emphasizes that the occurrence of gastric cancer in young patients remains largely unexplained, and is probably caused by a predisposing genotype that has facilitated cancer development due various environmental triggers[39].

**Table 1 Environmental and other risk factors for conventional gastric cancer**

| Increased risk of gastric cancer | Decreased risk of gastric cancer |
|---------------------------------|--------------------------------|
| CHD1, TP53, BRCA2 germline mutation | Fruit and vegetables |
| Hereditary non-polyposis colorectal cancer | Ascorbic acid |
| Helicobacter pylori infection | Carotenoids |
| Epstein bavirus infection | Folates |
| Cigarette smoking | Tocopherols |
| Smoked or cured meat and fish | Cereal fibres |
| Pickled vegetables | Numerous polymorphisms |
| Chilli peppers | (as mentioned under increased risk) |
| Alcohol | |
| Exposure to nitrosamines + inorganic dust | |
| Obesity | |
| Pharmacological gastric acid suppression | |
| IL-1β-31 polymorphism | |
| 1195 COX-2 polymorphism | |
| Other polymorphisms: MTHFR, PSMA, XPA, XPC, ERCC2, GSTT1, SULT1A1, NAT2, EPHX1, Toll-like receptor 4 | |

*WJGO* 2010, 1, 000-000
It has been discovered that EOGCs have a different clinicopathological profile than conventional gastric carcinomas. This suggests that they represent a separate entity within gastric carcinogenesis and indeed evidence at a molecular genetic level supports this. The majority of gastric adenocarcinomas, like many other solid tumours, show defects in the maintenance of genome stability, resulting in DNA copy number alteration that can be analysed by (microarray-based) comparative genomic hybridization (array CGH). Hierarchical cluster analysis of array CGH data on 46 gastric cancer patients (including 12 young patients) revealed clusters with genomic profiles that correlated significantly with age. Gains at chromosomes 17q, 19q and 20q have been found in EOGC with comparative genomic hybridization and LOH findings have also shown that losses are infrequent in EOGC.

The presence of microsatellite instability (MSI), which usually occurs at a frequency of 15%-20% in older gastric carcinomas, also varies dramatically between gastric cancer in young and old patients, with MSI consistently absent in EOGC. This contrasts with the situation in colorectal cancer in young and old patients, with MSI consistently present in colorectal cancer in young patients. In colorectal cancer, MSI is usually more common and inclusion of mixed and intestinal type tumours (diffuse tumours generally have less MSI) have been found despite the analysis of distal tumours (where MSI is usually more common) and inclusion of mixed and intestinal type tumours (diffuse tumours generally have less MSI). However, it may be that geographical factors play a role. A lack of MSI excludes the mutator phenotype as an important predisposing factor in the development of EOGC. This contrasts with the situation in colorectal cancer where 58% of patients without HNPCC aged under 35 years showed evidence of MSI. EOGC also contrasts with colorectal cancer with respect to the tumor suppressor gene APC, which causes familial adenomatosis polyposis syndrome. The role of APC in EOGC is limited and nuclear expression of β-catenin has not been found to differ between EOGC and conventional gastric cancers.

Molecular expression profiles of EOGC and conventional gastric cancers have been found to differ and EOGC has a COX-2 Low, TFF-1 expressing phenotype. In light of studies showing the reduced risk of gastric cancer in non-steroidal anti-inflammatory drug users, these results may have clinical implications, as they suggest that this reduced risk may apply only to gastric cancer in older patients, as COX-2 does not appear to play an important role in EOGC. It also implies that genetic changes typical for conventional tumors more readily induce COX-2 expression than those associated with EOGC. Interestingly, this COX-2 low phenotype cannot be explained by the increased presence of the COX2 -765 G>C polymorphism in EOGC. A higher incidence of aberrant E-cadherin expression in EOGC regardless of histological type has also been reported, although a more recent report that compared EOGC with conventional cancers showed that aberrant expression of E-cadherin correlated significantly with the diffuse type.

Deregulation of the cell cycle is known to be a critical event in the onset of tumourigenesis, and thus the finding of low molecular weight isoforms of cyclin E in EOGC, which are reported to be constitutively active in breast cancer, are of great interest. The expression of these isoforms differs between EOGC and conventional cancers, being present in 35% of EOGCs, compared to in 8% of conventional gastric cancers and 4% of stump cancers. In addition, these low molecular weight isoforms in EOGC diverge from the classical role of cyclin E as oncogenes and were found to be an independent positive prognostic indicator in EOGC adding to reports where the role of cyclin E conflicted with previous dogma. This complexity of molecular wiring in carcinogenesis has also been emphasized in recent literature, with the conclusion that cancer can no longer be understood as a multi-step pathway but rather a complex process where we can learn from the young.
was found that overexpression of the isoform CD44v6 correlated with this amplification in diffuse type cancer and that this overexpression occurred more commonly in EOGC regardless of histological type [57].

The gene RUNX3 has been a subject of great debate in gastric cancer studies in recent years, following a study where loss of the gene was shown to be associated with stimulated proliferation and suppressed apoptosis of gastric epithelial cells [49]. Conflicting evidence has, however, also been present, as the expression of RUNX3 in the gastric mucosa of mice differed significantly between strains analysed [58]. Furthermore, the gastric hyperplasia observed in the Runx3-/ mice used in Li’s study was not observed in the mouse strain studied by Levanon et al [58]. Recent literature regarding RUNX3 has excluded it as having a tumour suppressor function in EOGC, although as some of the cell lines used in this study were from conventional gastric cancers, the implications may be more far-reaching and call the importance of RUNX3 in all gastric cancers into question.

Classic genetics alone cannot explain sporadic EOGC and cancer development in patients with a weak family history. The concept of epigenetics offers a partial explanation and may have important clinical implications for these types of cancer. The best-known epigenetic marker is DNA methylation, which occurs in CpG sites (islands), has critical roles in the control of gene activity, and is influenced by the modifications in histone structure that are commonly disrupted in cancer cells. Gene promoter methylation, a phenomenon that increases with age and may account for the increase in cancer in older age groups, has also been found to occur in EOGC [57]. However, comparison with the conventional group has not yet been carried out.

As supported by the literature, summarised in Table 2, EOGCs differ from conventional gastric cancers, not only at a clinicopathological level, but also at a molecular genetic level. If this is indeed due to the fact that the environment plays a smaller role in triggering the carcinogenic pathway, the investigation of this group of cancers may reveal genetic changes that assist in the task of putting forward a multistep pathway for gastric cancer.

| Conventional gastric cancer | Early-onset gastric cancer | Ref. |
|----------------------------|--------------------------|------|
| Equally common in male and females | More common in females | [57] |
| Intestinal type cancer more common | Diffuse type cancer more common | [57] |
| Usually unifocal | Often multifocal | [57] |
| Often preceded by intestinal metaplasia | No intestinal metaplasia | [57] |
| Micronucleotide Instability in 15%-20% | Lack of MSI | [57] |
| Commonly find loss of heterozygosity | Infrequent loss of heterozygosity | [57] |
| COX2 overexpression in 66% | COX2 overexpression in 10% | [57] |
| Loss of TFF1 expression in 73% | Loss of TFF1 expression in 39% | [57] |
| Loss of RUNX3 gene | No loss of RUNX3 | [57] |
| Widespread gains throughout genome | Gains at chromosomes 17q, 19q and 20q | [57] |
| Distinct gene clusters on hierarchical analysis | Distinct gene clusters on hierarchical analysis | [57] |
| Infrquent LMW isoforms of cyclin E | Frequent LMW isoforms of cyclin E | [57] |
| CD44v6 expression | CD44v6 more commonly expressed | [57] |
| Usually no family history | 10% with a family history | [57] |

**FUTURE PROSPECTIVES**

Gastric carcinoma continues to be a cause of premature death, despite progress in detection and treatment and despite advances in our understanding of the molecular basis of cancer. The need to develop efficient and effective cancer-specific drugs is coupled with the importance of accurate prediction of disease outcome for various patient groups, some of whom, due to the biology of their disease, will do better than others and may warrant a different treatment protocol. However, the multi-step pathway of carcinogenesis that occurs in some epithelial cancers and that has allowed accurate clinical and pathologic characterization is not yet elucidated in gastric cancer. Gastric cancers often occur without any consistent mutational abnormality and with considerable variation in pathogenesis ranging from a stepwise progression of changes to tumours arising in the absence of a precursor lesion. As has been highlighted in this article, there is growing evidence to support the hypothesis that young patients develop carcinomas with a different molecular genetic profile from that of sporadic carcinomas occurring at a later age. Further study of hereditary gastric cancers and EOGC as unique subsets of gastric cancer may aid us in the search for a gastric cancer pathway.

**REFERENCES**

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
2. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitras F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-1305
3. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186
5. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 2007; 7: 15-28
6. Milne AN, Carneiro F, O’Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009; 126: 615-628
Milestone AN et al. Early-onset gastric cancer

7 Craenen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Intestinal metaplasia and Helicobacter pylori: an endoscopic biotic study of the gastric antrum. Gut 1992; 33: 16-20

8 Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115: 642-648

9 El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402

10 Lauren P. The Two Histological Main Types of Gastric Carcinomata: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 1965; 64: 31-49

11 Hamilton SR, Aaltenon LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press, 2000: 204

12 Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itoh M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubin CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe Y, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255

13 Kokkola A, Sipponen P. Gastric carcinoma in young adults. Hepatogastroenterology 2001; 48: 1552-1555

14 Umeyama K, Sowa M, Kamin K, Kato Y, Satake K. Gastric carcinoma in young adults in Japan. Acta Pathol Jpn 1982; 2: 283-286

15 Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H. Clinicopathologic characteristics of gastric cancer in a young patient population. J Gastrointest Surg 2004; 8: 240-244

16 Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54: 1941s-1943s

17 Rugge M, Busatto G, Casaro M, Shiao YH, Russo V, Leandro G, Avellini C, Fabiano A, Sidoni A, Covacci A. Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer 1999; 85: 2506-2511

18 Koshida Y, Koizumi W, Sasabe M, Katoh Y, Okayasu I. Association of Helicobacter pylori-dependent gastritis with gastric carcinomas in young Japanese patients: histopathological comparison of diffuse and intestinal type cancer cases. Histopathology 2000; 37: 124-130

19 Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol 2000; 35: 255-259

20 Sitarz R, de Leng WW, Polak M, Morsink FH, Bakker O, Polkowski WP, Maciejewski R, Offerhaus GJ, Milne AN. IL-1β-31T>C promoter polymorphism is associated with gastric stromal tumors but not with early onset or conventional gastric cancers. Virchows Arch 2008; 453: 249-255

21 Rugge M, Genta RM. Epstein-Barr virus: a possible accomplice in gastric oncogenesis. J Clin Gastroenterol 1999; 29: 3-5

22 Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992; 140: 769-774

23 Shibata D, Hayes D, Stemmermann GN, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma among Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1993; 2: 213-217

24 Carvalho R, Milne AN, van Rees BP, Caspers E, Cirmes L, Figueredo C, Offerhaus GJ, Weterman MA. Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol 2004; 204: 75-83

25 Maehara Y, Eri M, Tomisaki S, Oshiro T, Kakeji Y, Ichiyoshi Y, Sugimachi K. Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 1996; 77: 1774-1780

26 Theuer CP, de Virgilio F, Keese G, French S, Arnett T, Tolomos J, Klein S, Powers W, Ole T, Stabile BE. Gastric adenocarcinoma in patients 40 years of age or younger. Am J Surg 1996; 172: 473-476; discussion 476-477

27 Medina-Franco H, Heslin MJ, Cortes-Gonzalez R. Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol 2000; 7: 515-519

28 Matley PJ, Dont DM, Madden MV, Price SK. Gastric carcinoma in young adults. Ann Surg 1988; 208: 593-596

29 Lim S, Lee HS, Kim HS, Kim YI, Kim WH. Alteration of E-cadherin-mediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology 2003; 42: 128-136

30 Maeta M, Yamashiro H, Oka A, Tsujitani S, Ikeguchi M, Kaibara N. Gastric cancer in the young, with special reference to 14 pregnancy-associated cases: analysis based on 2,235 consecutive cases of gastric cancer. J Surg Oncol 1995; 58: 191-198

31 Derakhshan MH, Liproit S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58: 16-23

32 Furukawa H, Iwanga T, Imaoka S, Hinatsu K, Fukuda I, Kabuto T, Ishikawa O, Sasaki Y. Multifocal gastric cancer in patients younger than 50 years of age. Eur J Surg 1989; 21: 313-318

33 Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simões M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203: 681-687

34 Suriano G, Oliveira C, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C, Seruca R. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003; 12: 575-582

35 Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser M, Kaibara N. Gastric cancer in the young, with special reference to 14 pregnancy-associated cases: analysis based on 2,325 consecutive cases of gastric cancer. J Surg Oncol 1993; 53: 140-146

36 Riddell RH, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simões M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203: 681-687

37 Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008; 61: 25-30

38 Bacani JT, Soares M, Zwingerman R, di Nicola N, Senz J, Riddell R, Huntsman DG, Gallinger S. CDH1/E-cadherin germline mutations in early-onset gastric cancer. J Med Genet 2006; 43: 867-872

39 Bacani J, Zwingerman R, di Nicola N, Spencer S, Wegrynowski T, Mitchell K, Hay K, Redston M, Holowaty E, Huntsman D, Pollett A, Riddell R, Gallinger S. Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn 2005; 7: 465-477

40 Buffett TE, Carvalho B, Hopmans E, Brehm V, Kraneberg EK, Schaaij-Visser TB, Eijk PP, van Grieken NC, Ylst B, van de Velde CJ, Meijer GA. Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 2007; 211: 45-51

41 Varis A, van Rees B, Weterman M, Ristimaki A, Offerhaus...
Early-onset gastric cancer

J. Knuttila S. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer 2003; 88: 1914-1919

Hayden JD, Cawkwell L, Sue-Ling H, Johnston D, Dixon MF, Quirke P, Martin IG. Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. Cancer 1997; 80: 684-687

Carneiro F, Oliveira C, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer. Semin Diagn Pathol 2008; 25: 274-287

Seruca R, Sobrinho-Simões M. Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. Cancer 1997; 80: 1338-1360

Hayden JD. Cawkwell L, Dixon MF, Pardal F, Murgatroyd H, Gray S, Quirke P, Martin IG. A comparison of microsatellite instability in early onset gastric carcinomas from relatively low and high incidence European populations. Int J Cancer 2000; 85: 189-191

Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, Fujiwara T, Jen J, Kinzler KW, Wylie AH. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1: 348-352

Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimäki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006; 19: 564-572

Kim HC, Kim JC, Roh SA, Yu CS, Yook JH, Oh ST, Kim BS, Park KC, Chang R. Aberrant CpG island methylation in early-onset sporadic gastric carcinoma. J Cancer Res Clin Oncol 2005; 131: 733-740

Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642-1646

Akre K, Ekström AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84: 965-968

Sitras R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ, Milne AN. The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol 2008; 21: 685-690

Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995; 11: 941-950

Milne AN. Carvalho R, Jansen M, Kranenburg EK, van de Velde CJ, Morsink FM, Musler AR, Weterman MA, Offerhaus GJ. Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 2008; 61: 311-316

Berglund P, Stighall M, Jirstöm K, Borgquist S, Sjölander A, Hedenfalk I, Landberg G. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. Cancer Res 2005; 65: 9727-9734

Takano Y, Kato Y, van Dien PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156: 585-594

Ishikawa Y. Wnt signaling and orthopedic diseases. Am J Pathol 2005; 167: 1-3

Sharpless NE, DePinho RA. Cancer: crime and punishment. Nature 2005; 436: 636-637

Carvalho R, Milne AN, Polak M, Offerhaus GJ, Weterman MA. A novel region of amplification at 11p12-13 in gastric cancer, revealed by representational difference analysis, is associated with overexpression of CD44v6, especially in early-onset gastric carcinomas. Genes Chromosomes Cancer 2006; 45: 967-975

Li QL, Ito K, Sakakura C, Fukushima H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124

Levannon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep 2003; 4: 560-564

Levannon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldberg D, Xiao C, Fliegauf M, Krainer E, Otto F, Brenner O, Lev-Toaff A, Groner Y. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 2002; 21: 3454-3463

Carvalho R, Milne AN, Polak M, Corver WE, Offerhaus GJ, Weterman MA. Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas. Oncogene 2005; 24: 8252-8258

S-Editor Li LF  L-Editor Lutze M  E-Editor Lin YP